The expanded services and capabilities include the storage, kitting, and distribution of advanced cell and gene therapies at ultra-low temperatures for clinical trials.

George Buchman, Ph.D., will present at the upcoming 26th Annual Meeting of the American Society of Gene and Cell Therapy, which is being held in Los Angeles on May 16-20, 2023.

Julien Meissonnier will present at the upcoming 4th Symposium of the International Consortium for Advanced Medicines Manufacturing (ICAMM), to be held at the Royal Sonesta Hotel, Cambridge, Massachusetts, on April 27 – 28, 2023.

Catalent today announced that two of its clinical supply experts are to co-host workshop sessions at the upcoming Global Clinical Supplies Group (GCSG) Conference, to be held in Orlando, Florida, on April 23 – 26, 2023.

Catalent today announced that it has begun construction of a $20 million expansion project at its clinical supply facility in Schorndorf, Germany.

The Catalent Applied Drug Delivery Institute, which was established as a cross-industry consortium to accelerate the adoption of advanced drug delivery technologies, announces that it will hold a symposium in affiliation with Johnson & Johnson Innovation – JLABS (JLABS).

The launch of the ProteoSuiteSM Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into clinical trials.

Under its terms, Catalent will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™ (3.0 mg), for the emergency treatment of known or suspected opioid overdose.

Under the terms of the agreement, Catalent is authorized to collaborate with its customers to evaluate BRL’s formulation technology to reduce viscosity and deliver high-concentration biologic products.